Calithera Biosciences CALA

$ 0.37 -10.95%

Quarterly report 2022-Q3
added 11-14-2022

Calithera Biosciences Balance Sheet 2011-2024 | CALA

Annual Balance Sheet Calithera Biosciences

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-56.5 M	-97.5 M	-52.2 M	-51.1 M	-48.5 M	-10.6 M	-6.1 M	-102 M	-33.8 M	-2.2 M	-
Long Term Debt	1.67 M	4.82 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.37 M	1.9 M	1.48 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	4.82 M	6.72 M	1.13 M	3.12 M	437 K	129 K	283 K	54.3 M	10.7 M	-
Total Current Liabilities	14 M	18.4 M	19.6 M	14.9 M	39 M	4.45 M	3.83 M	4.12 M	-	-	-
Total Liabilities	15.7 M	23.2 M	26.3 M	16 M	42.1 M	4.89 M	3.96 M	4.4 M	55.7 M	11.6 M	-
Deferred Revenue	-	-	1.55 M	2.47 M	29 M	-	-	-	-	-	-
Retained Earnings	-491 M	-376 M	-286 M	-196 M	-150 M	-123 M	-84.5 M	-51.9 M	-30.1 M	-17.8 M	-
Total Assets	64.8 M	126 M	169 M	143 M	192 M	54.8 M	75.8 M	105 M	34.8 M	3.06 M	-
Cash and Cash Equivalents	59.5 M	107 M	60.4 M	51.1 M	48.5 M	10.6 M	6.1 M	102 M	33.8 M	2.2 M	-
Book Value	49.1 M	102 M	142 M	127 M	150 M	49.9 M	71.8 M	100 M	-20.8 M	-8.57 M	-
Total Shareholders Equity	8.38 M	102 M	142 M	127 M	150 M	49.9 M	71.8 M	100 M	-20.8 M	-8.57 M	-

All numbers in USD currency

Quarterly Balance Sheet Calithera Biosciences

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	533 K	917 K	1.3 M	1.67 M	2.02 M	2.37 M	2.71 M	4.82 M	4.82 M	4.82 M	4.82 M	6.72 M	6.72 M	6.72 M	6.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	292 K	-	-	31 K	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	10.7 M	10.3 M	12.7 M	15.7 M	15.6 M	14.8 M	16.5 M	23.2 M	23.2 M	23.2 M	23.2 M	26.3 M	26.3 M	26.3 M	26.3 M	16 M	16 M	16 M	16 M	42.1 M	42.1 M	42.1 M	42.1 M	4.89 M	4.89 M	4.89 M	4.89 M	3.96 M	3.96 M	3.96 M	3.96 M	4.4 M	4.4 M	4.4 M	4.4 M	1.38 M	1.38 M	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.1 M	29 M	29 M	29 M	29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-506 M	-496 M	-505 M	-491 M	-422 M	-411 M	-397 M	-376 M	-376 M	-376 M	-376 M	-286 M	-286 M	-286 M	-286 M	-196 M	-196 M	-196 M	-196 M	-150 M	-150 M	-150 M	-150 M	-123 M	-123 M	-123 M	-123 M	-84.5 M	-84.5 M	-84.5 M	-84.5 M	-51.9 M	-51.9 M	-51.9 M	-51.9 M	-30.1 M	-30.1 M	-	-	-	-	-	-	-	-	-	-
Total Assets	-	37.1 M	45.6 M	50.2 M	64.8 M	90 M	97.9 M	111 M	126 M	126 M	126 M	126 M	169 M	169 M	169 M	169 M	143 M	143 M	143 M	143 M	192 M	192 M	192 M	192 M	54.8 M	54.8 M	54.8 M	54.8 M	75.8 M	75.8 M	75.8 M	75.8 M	105 M	105 M	105 M	105 M	34.8 M	34.8 M	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	34.1 M	41.8 M	44.7 M	59.5 M	84.5 M	92.2 M	101 M	107 M	107 M	107 M	107 M	60.4 M	60.4 M	60.4 M	60.4 M	51.1 M	51.1 M	51.1 M	51.1 M	48.5 M	48.5 M	48.5 M	48.5 M	10.6 M	10.6 M	10.6 M	10.6 M	6.1 M	6.1 M	6.1 M	6.1 M	102 M	102 M	102 M	102 M	33.8 M	33.8 M	-	-	2.2 M	-	-	-	3.28 M	-	-	-
Book Value	-	26.4 M	35.3 M	37.6 M	49.1 M	74.4 M	83 M	94.2 M	102 M	102 M	102 M	102 M	142 M	142 M	142 M	142 M	127 M	127 M	127 M	127 M	150 M	150 M	150 M	150 M	49.9 M	49.9 M	49.9 M	49.9 M	71.8 M	71.8 M	71.8 M	71.8 M	100 M	100 M	100 M	100 M	33.5 M	33.5 M	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	26.4 M	35.3 M	-3.14 M	8.38 M	74.4 M	83 M	94.2 M	102 M	102 M	102 M	102 M	142 M	142 M	142 M	142 M	127 M	127 M	127 M	127 M	150 M	150 M	150 M	150 M	49.9 M	49.9 M	49.9 M	49.9 M	71.8 M	71.8 M	71.8 M	71.8 M	100 M	100 M	100 M	100 M	-20.8 M	-20.8 M	-	-	-8.57 M	-	-	-	-3.56 M	-	-	-

All numbers in USD currency